As GLP-1 Shortages Ease, Patient Safety Concerns Shift to Unsafe Copies
The end of key GLP-1 drug shortages has not ended concerns about unsafe compounded, counterfeit and unapproved products. FDA warnings point to dosing errors, questionable ingredients and counterfeit drugs that may put patients at risk, especially as cost and coverage barriers continue to affect access to approved treatments.
As GLP-1 Shortages Ease, Patient Safety Concerns Shift to Unsafe Copies Read More »
